Lysophosphatidic Acid Aberrancies and Hepatocellular Carcinoma: Studies in the MDR2 Gene Knockout Mouse

REFERENCES

• Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461–466.
   PubMed Web of Science ®Google Scholar
• Werner H. Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer. Oncogene 2011;31:2703–2714.
   Google Scholar
• Houben AJ, Moolenaar WH. Autotaxin and LPA receptor signaling in cancer. Cancer Metast Rev. 2011;30:557–565.
   PubMed Web of Science ®Google Scholar
• Fojo A, Lebo R, Shimizu N, Chin JE, Roninson IB, Merlino GT, Gottesman MM, Pastan I. Localization of multidrug resistance-associated DNA sequences to human chromosome 7. Somat Cell Mol Genet 1986;12:415–420.
   PubMedGoogle Scholar
• Smit JJ, Schinkel AH, Oude Elferink RP, Groen AK, Wagenaar E, van Deemter L, Mol CA, Ottenhoff R, van der Lugt NM, van Roon MA, Mola CAAM, Ottenhoffb, R, van der Lugtc NMT, van Roon, MA, Van der Valkc MA, Offerhausd GJA, Berns AJM, Borst P. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 1993;75:451–462.
   PubMed Web of Science ®Google Scholar
• Mauad TH, van Nieuwkerk CM, Dingemans KP, Smit JJ, Schinkel AH, Notenboom RG, van den Bergh Weerman MA, Verkruisen RP, Groen AK, Oude Elferink RP, van der Valk MA, Borst P, Offerhaus GJA. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol 1994;145:1237–1245.
   PubMed Web of Science ®Google Scholar
• Teeter LD, Chan JY, Kuo MT. Coordinate activation of multidrug-resistance (P-glycoprotein) genes mdr2 and mdr3 during mouse liver regeneration. Mol Carcinogen 1991;4:358–361.
   PubMed Web of Science ®Google Scholar
• Pirker R, Wallner J, Gsur A, Gotzl M, Zochbauer S, Scheithauer W, Depisch D. MDR1 gene expression in primary colorectal carcinomas. Br J Cancer 1993;68:691–694.
   PubMed Web of Science ®Google Scholar
• Teeter L, Hsu H, Curley S, Tong M, Kuo M. Expression of multidrug resistance (p-glycoprotein) mdr1 and mdr2 genes in human hepatocellular carcinomas and liver metastases of colonic tumors. Int J Oncol 1993;2:73–80.
   PubMed Web of Science ®Google Scholar
• Omar HA, Chou CC, Berman-Booty LD, Ma Y, Hung JH, Wang D, Kogure T, Patel T, Terracciano L, Muthusamy N, Byrd JC, Kulp SK, Chen CS. Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology 2011;53:1943–1958.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Xiao Y, Elson P, Tan H, Plummer SJ, Berk M, Aung PP, Lavery IC, Achkar JP, Li L, Casey G, Xu Y. Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer. J Clin Oncol 2007;25:2696–1701.
   PubMed Web of Science ®Google Scholar
• Xu X, Yang G, Zhang H, Prestwich GD. Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumors. Prostaglandins Other Lipid Media. 2009;89:140–146.
   PubMed Web of Science ®Google Scholar
• Abel S, De Kock M, van Schalkwyk DJ, Swanevelder S, Kew MC, Gelderblom WC. Altered lipid profile, oxidative status and hepatitis B virus interactions in human hepatocellular carcinoma. Prostaglandins Leukot Essent Fatty Acids. 2009;81:391–399.
   PubMed Web of Science ®Google Scholar
• Taylor LA, Arends J, Hodina AK, Unger C, Massing U. Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status. Lipids Health Dis. 2007;6:6–17.
   Google Scholar
• Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, Lin ME, Teo ST, Park KE, Mosley AN, Chun J. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 2010;50:157–186.
   PubMed Web of Science ®Google Scholar
• Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV. The role of cAMP-MAPK signalling in the regulation of human hepatocellular carcinoma growth in vitro. Eur J Gastroen Hepat 1999;11:1393–1399.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee R, Xiang W, Wang Y, Zhang X, Billiar TR. cAMP prevents TNF-induced apoptosis through inhibiting DISC complex formation in rat hepatocytes. Biochem Bioph Res Commun 2012;423:85–90.
   PubMed Web of Science ®Google Scholar
• Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP, 3rd, Larrick J, Kunkel SL. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Bioph Res Commun 1988;155:1230–1236.
   PubMed Web of Science ®Google Scholar
• Skill NJ, Scott RE, Wu J, Maluccio MA. Hepatocellular carcinoma associated lipid metabolism reprogramming. J Surg Res 169:51–56.
   PubMed Web of Science ®Google Scholar
• Shiratori Y, Yoshida H, Omata M. Effects of interferon therapy on inhibition of hepatocellular carcinoma development in patients with chronic hepatitis C. JPN J Clin Oncol 2000;30:213–214.
   PubMed Web of Science ®Google Scholar
• Alison MR, Nicholson LJ, Lin WR. Chronic inflammation and hepatocellular carcinoma. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer. 2011;185:135–148.
   Google Scholar
• Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, North BV, Kubota K, Sharma R. A novel and validated prognostic index in hepatocellular carcinoma: the Inflammation Based Index (IBI). J Hepatol 2012;57:1013–1020.
   Google Scholar
• Barash H, Gross ER, Edrei Y, Ella E, Israel A, Cohen I, Corchia N, Ben-Moshe T, Pappo O, Pikarsky E, Goldenberg D, Shiloh Y, Galun E, Abramovitch R. Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. Proc Natl Acad Sci USA 107:2207–2212.
   PubMed Web of Science ®Google Scholar
• Klopstock N, Katzenellenbogen M, Pappo O, Sklair-Levy M, Olam D, Mizrahi L, Potikha T, Galun E, Goldenberg D. HCV tumor promoting effect is dependent on host genetic background. PloS One 2009;4:e5025, 1–11.
   Google Scholar
• Barikbin R, Neureiter D, Wirth J, Erhardt A, Schwinge D, Kluwe J, Schramm C, Tiegs G, Sass G. Induction of heme oxygenase 1 prevents progression of liver fibrosis in Mdr2 knockout mice. Hepatology 2012;55:553–562.
   PubMed Web of Science ®Google Scholar
• Strack I, Schulte S, Varnholt H, Schievenbusch S, Tox U, Wendland K, Steffen HM, Drebber U, Dienes HP, Odenthal M. Beta-Adrenoceptor blockade in sclerosing cholangitis of Mdr2 knockout mice: antifibrotic effects in a model of nonsinusoidal fibrosis. Lab Invest J Tech Meth Pathol 2011;91:252–261.
   PubMed Web of Science ®Google Scholar
• Wu JM, Skill NJ, Maluccio MA. Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma. HPB (Oxford) 12:625–636.
   PubMedGoogle Scholar
• Takeba Y, Matsumoto N, Watanabe M, Takenoshita-Nakaya S, Ohta Y, Kumai T, Takagi M, Koizumi S, Asakura T, Otsubo T. The Rho kinase inhibitor fasudil is involved in p53-mediated apoptosis in human hepatocellular carcinoma cells. Cancer Chemoth Pharm 2012;69:1545–1555.
   PubMed Web of Science ®Google Scholar
• Yanagida K, Masago K, Nakanishi H, Kihara Y, Hamano F, Tajima Y, Taguchi R, Shimizu T, Ishii S. Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J Biol Chem 2009;284:17731–17741.
   PubMed Web of Science ®Google Scholar
• Lee CW, Rivera R, Gardell S, Dubin AE, Chun J. GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem 2006;281:23589–23597.
   PubMed Web of Science ®Google Scholar
• Kassahun WT, Gunl B, Jonas S, Ungemach FR, Abraham G. Altered liver alpha1-adrenoceptor density and phospholipase C activity in the human hepatocellular carcinoma. Eur J Pharmacol 2011;670:92–95.
   PubMed Web of Science ®Google Scholar
• Takeishi K, Taketomi A, Shirabe K, Toshima T, Motomura T, Ikegami T, Yoshizumi T, Sakane F, Maehara Y. Diacylglycerol kinase alpha enhances hepatocellular carcinoma progression by activation of Ras-Raf-MEK-ERK pathway. J Pharmacol 2012;57:77–83.
   Google Scholar
• Dituri F, Mazzocca A, Lupo L, Edling CE, Azzariti A, Antonaci S, Falasca M, Giannelli G. PI3K class IB controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma. Int J Cancer J Int du Cancer 2012;130:2505–2513.
   PubMed Web of Science ®Google Scholar
• Cordero JB, Macagno JP, Stefanatos RK, Strathdee KE, Cagan RL, Vidal M. Oncogenic Ras diverts a host TNF tumor suppressor activity into tumor promoter. Dev Cell 2010;18:999–1011.
   PubMed Web of Science ®Google Scholar
• Monick MM, Powers LS, Butler NS, Hunninghake GW. Inhibition of Rho family GTPases results in increased TNF-alpha production after lipopolysaccharide exposure. J Immunol 2003;171:2625–2630.
   PubMed Web of Science ®Google Scholar
• Kim YM, Lee YM, Kim HS, Kim JD, Choi Y, Kim KW, Lee SY, Kwon YG. TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells. J Biol Chem 2002;277:6799–6805.
   PubMed Web of Science ®Google Scholar
• Kramer PR, Winger V, Reuben J. PI3K limits TNF-alpha production in CD16-activated monocytes. Eur J Immunol 2009;39:561–570.
   PubMed Web of Science ®Google Scholar
• Foey AD, Field S, Ahmed S, Jain A, Feldmann M, Brennan FM, Williams R. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis. Arthrit Res Ther 2003;5:R317–R328.
   Google Scholar
• Wall EA, Zavzavadjian JR, Chang MS, Randhawa B, Zhu X, Hsueh RC, Liu J, Driver A, Bao XR, Sternweis PC, Simon MI, Fraser ID. Suppression of LPS-induced TNF-alpha production in macrophages by cAMP is mediated by PKA-AKAP95-p105. Sci Signaling 2009;2:ra28, 1–17.
   Google Scholar
• Bertazza L, Mocellin S. The dual role of tumor necrosis factor (TNF) in cancer biology. Curr Med Chem 2010;17:3337–3352.
   PubMed Web of Science ®Google Scholar
• Barekzi E, Roman J, Hise K, Georas S, Steinke JW. Lysophosphatidic acid stimulates inflammatory cascade in airway epithelial cells. Prostaglandins Leukot Essent Fatty Acids 2006;74:357–363.
   PubMed Web of Science ®Google Scholar
• Xue J, Gan L, Li X, Li J, Qi G, Wu Y, Fu X, Mao Q, Ao R, Lang J, Lu Y. Effects of lysophosphatidic acid and its receptors LPA(1/3) on radiation pneumonitis. Oncol Rep 24:1515–1520.
   PubMed Web of Science ®Google Scholar
• Le Gall SM, Maretzky T, Issuree PD, Niu XD, Reiss K, Saftig P, Khokha R, Lundell D, Blobel CP. ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site. J Cell Sci 123:3913–3922.
   PubMed Web of Science ®Google Scholar
• Matsuzaki S, Ishizuka T, Hisada T, Aoki H, Komachi M, Ichimonji I, Utsugi M, Ono A, Koga Y, Dobashi K, Kurose H, Tomura H, Mori M, Okajima F. Lysophosphatidic acid inhibits CC chemokine ligand 5/RANTES production by blocking IRF-1-mediated gene transcription in human bronchial epithelial cells. J Immunol 185:4863–4872.
   PubMed Web of Science ®Google Scholar
• Ehlken H, Kondylis V, Heinrichsdorff J, Ochoa-Callejero L, Roskams T, Pasparakis M. Hepatocyte IKK2 protects Mdr2−/− mice from chronic liver failure. PloS One 2011;6:e25942, 1–10.
   Google Scholar
• Xu MY, Porte J, Knox AJ, Weinreb PH, Maher TM, Violette SM, McAnulty RJ, Sheppard D, Jenkins G. Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). Am J Pathol 2009;174:1264–1279.
   PubMed Web of Science ®Google Scholar
• Cabello-Verrugio C, Cordova G, Vial C, Zuniga LM, Brandan E. Connective tissue growth factor induction by lysophosphatidic acid requires transactivation of transforming growth factor type beta receptors and the JNK pathway. Cell Signal 23:449–457.
   PubMed Web of Science ®Google Scholar
• So J, Wang FQ, Navari J, Schreher J, Fishman DA. LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynecol Oncol 2005;97:870–878.
   PubMed Web of Science ®Google Scholar
• Hu X, Mendoza FJ, Sun J, Banerji V, Johnston JB, Gibson SB. Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies. Cell Signal 2008;20:1198–1208.
   PubMed Web of Science ®Google Scholar
• Sako A, Kitayama J, Shida D, Suzuki R, Sakai T, Ohta H, Nagawa H. Lysophosphatidic acid (LPA)-induced vascular endothelial growth factor (VEGF) by mesothelial cells and quantification of host-derived VEGF in malignant ascites. J Surg Res 2006;130:94–101.
   PubMed Web of Science ®Google Scholar
• Hirasaki S, Koide N, Ujike K, Shinji T, Tsuji T. Expression of Nov, CYR61 and CTGF genes in human hepatocellular carcinoma. Hepatol Res Off J JPN Soc Hepatol 2001;19:294–305.
   PubMed Web of Science ®Google Scholar
• Mazzocca A, Antonaci S, Giannelli G. The TGF-beta signaling pathway as a pharmacological target in hepatocellular carcinoma. Curr Pharm Design 2012;18:4148–4154.
   Google Scholar
• Zhang L, Wang JN, Tang JM, Kong X, Yang JY, Zheng F, Guo LY, Huang YZ, Zhang L, Tian L, Cao SF, Tuo CH, Guo HL, Chen SY. VEGF is essential for the growth and migration of human hepatocellular carcinoma cells. Mol Biol Rep 2012;39:5085–5093.
   PubMed Web of Science ®Google Scholar
• Ushitora Y, Tashiro H, Ogawa T, Tanimoto Y, Kuroda S, Kobayashi T, Miyata Y, Itamoto T, Asahara T, Ohdan H. Suppression of hepatocellular carcinoma recurrence after rat liver transplantation by FTY720, a sphingosine-1-phosphate analog. Transplantation 2009;88:980–986.
   PubMed Web of Science ®Google Scholar